Neumora Therapeutics, Inc. (NMRA) analyst actions
Rating and price-target actions on NMRA in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the NMRA overview →
5 measured NMRA analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 | Press release | -3.67% | -0.37% | |
| Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861 | Press release | +4.44% | +13.33% | |
| Neumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation | Press release | +0.11% | -1.67% | |
| Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | Press release | +1.61% | +6.21% | |
| Neumora Therapeutics Announces NMRA-266 IND Clearance and Initiation of Phase 1 Clinical Study | Press release | +0.12% | -1.33% |
Keep exploring
More NMRA: earnings → · SEC filings → · NMRA overview →